Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | SPPL2A | Q8TCT8 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | ANPEP | P15144 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.45 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27724013 | 1.00 | LAP3 (0.47) | LAP3LTA4HSPPL2AABCB1ANPEP | |
| Hydrochloric Acid SCHEMBL3092868 | 0.99 | LAP3 (0.46) | LAP3LTA4HSPPL2AABCB1ANPEP | |
| SCHEMBL13538055 | 0.92 | LTA4H (0.60) | LAP3LTA4HREN | |
| SCHEMBL13541104 | 0.89 | REN (0.54) | LAP3LTA4HRENCSNK1E | |
| SCHEMBL13307522 | 0.88 | CTSB (0.51) | LAP3LTA4HSPPL2AABCB1ANPEP | |
| SCHEMBL3614651 | 0.84 | SPPL2A (0.52) | LAP3SPPL2AANPEPRNPEPDNPEP | |
| SCHEMBL7337419 | 0.84 | PSEN1 (0.46) | LAP3SPPL2AANPEPRNPEPDNPEP | |
| SCHEMBL5567381 | 0.84 | PSEN1 (0.46) | LAP3SPPL2AANPEPRNPEPDNPEP | |
| SCHEMBL13800207 | 0.82 | SPPL2A (0.41) | LAP3LTA4HSPPL2AANPEPRNPEP | |
| SCHEMBL27942343 | 0.82 | CTSB (0.52) | SPPL2AABCB1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9127029-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2015-09-08 | — | — | US | disclosed |
| US-9127029-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2015-09-08 | — | — | US | disclosed |
| EP-1960404-B1 | SUBSTITUTED AMINOPHENYLSULFONAMIDE COMPOUNDS AS HIV PROTEASE INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| EP-1960381-B1 | AMINOPHENYLSULFONAMIDE DERIVATIVES AS HIV PROTEASE INHIBITOR | JANSSEN SCIENCES IRELAND UC (IE) | 2015-06-17 | — | — | EP | disclosed |
| US-8877947-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2014-11-04 | — | — | US | disclosed |
| US-8877947-B2 | Process for preparation of substantially pure fosamprenavir calcium and its intermediates | LUPIN LIMITED (IN) | 2014-11-04 | — | — | US | disclosed |
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2014-09-11 | — | — | US | disclosed |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2013-07-11 | — | — | US | disclosed |
| WO-2012032389-A2 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | LUPIN LIMITED (IN) | 2012-03-15 | — | — | WO | disclosed |
| US-8084494-B2 | benzenesulfon-yl]-isobutyl-amino}-1-benzyl-2-hydroxy-propyl)-carbamic Acid hexahydro-furo[2,3-b]furan-3-yl Ester; anti-retroviral agent such as dextran sulfate, suramine etc. AIDS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-12-27 | — | — | US | disclosed |
| US-7803836-B2 | Aminophenylsulfonamide derivatives as HIV protease inhibitor | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-09-28 | — | — | US | disclosed |
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2008-12-11 | — | — | US | disclosed |
| US-20080269322-A1 | Substituted Aminophenylsulfonamide Compounds as Hiv Protease Inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256959-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | PLCB3, ITPR3, ITPR2 | LAP3 756/4885LTA4H 4053/4885SPPL2A 1150/4885 |
| US-20080269322-A1 | Substituted Aminophenylsulfonamide Compounds as Hiv Protease Inhibitor | DNPEP, ANPEP, NPEPPS | LAP3 48/4885LTA4H 841/4885SPPL2A 676/4885 |
| US-20130174651-A1 | PROCESS FOR PREPARATION OF SUBSTANTIALLY PURE FOSAMPRENAVIR CALCIUM AND ITS INTERMEDIATES | PLCB3, ITPR3, ITPR2 | LAP3 756/4885LTA4H 4053/4885SPPL2A 1150/4885 |
| US-20080306061-A1 | Aminophenylsulfonamide Derivatives as Hiv Protease Inhibitor | DNPEP, NPEPPS, ANPEP | LAP3 64/4885LTA4H 1385/4885SPPL2A 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.